GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK said it is holding steady in the face of ongoing regulatory and potential political pressures on its vaccines franchise, ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025.

GSK (LON: GSK) has issued an update which inevitably reflects the difficulties faced in the last year, while also providing a host of reasons to be more upbeat on future prospects. Concerns over the ...

GSK has today posted a better-than-expected fourth quarter and lifted its 2031 sales target to nearly $50 billion as the ...